Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy-Reference-Cited by-同舟云学术

Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy

Published:2024-01 Issue:1 Volume:12 Page:164-177
ISSN:2213-1779
Container-title:JACC: Heart Failure
language:en
Short-container-title:JACC: Heart Failure

Author:

Rader Florian^ORCID,Oręziak Artur^ORCID,Choudhury Lubna,Saberi Sara,Fermin David,Wheeler Matthew T.,Abraham Theodore P.,Garcia-Pavia Pablo^ORCID,Zwas Donna R.,Masri Ahmad,Owens Anjali,Hegde Sheila M.,Seidler Tim^ORCID,Fox Shawna,Balaratnam Ganesh,Sehnert Amy J.,Olivotto Iacopo

Funder

Bristol-Myers Squibb

Publisher

Elsevier BV

Reference17 articles.

1. Diagnosis and evaluation of hypertrophic cardiomyopathy: JACC state-of-the-art review;Maron;J Am Coll Cardiol,2022

2. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines;Gersh;J Am Coll Cardiol,2011

3. Progress with genetic cardiomyopathies: screening, counseling, and testing in dilated, hypertrophic, and arrhythmogenic right ventricular dysplasia/cardiomyopathy;Hershberger;Circ Heart Fail,2009

4. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines;Ommen;J Am Coll Cardiol,2020

5. Clinical course and management of hypertrophic cardiomyopathy;Maron;N Engl J Med,2018

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mavacamten for Obstructive Hypertrophic Cardiomyopathy: Rationale for Clinically Guided Dose Titration to Optimize Individual Response;Journal of the American Heart Association;2024-09-03

2. Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy;European Heart Journal;2024-09-01

3. Atrial Fibrillation in Hypertrophic Cardiomyopathy;JACC: Advances;2024-09

4. Mavacamten-Associated Temporal Changes in Left Atrial Function in Obstructive HCM;JACC: Cardiovascular Imaging;2024-09

5. A Real‑World Pharmacovigilance Study of FDA Adverse Event Reporting System (FAERS) for Mavacamten;American Journal of Cardiovascular Drugs;2024-08-21